发明公开
EP3150206A1 MEDICINAL COMPOSITION COMPRISING PYRAZINE CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT
审中-公开
维生素ZSAMMENSETZUNG MIT PYRAZIN-CARBOXAMID-VERBINDUNG ALS WIRKSTOFF
- 专利标题： MEDICINAL COMPOSITION COMPRISING PYRAZINE CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT
- 专利标题（中）： 维生素ZSAMMENSETZUNG MIT PYRAZIN-CARBOXAMID-VERBINDUNG ALS WIRKSTOFF
-
申请号： EP15799603.4申请日： 2015-05-27
-
公开(公告)号： EP3150206A1公开(公告)日： 2017-04-05
- 发明人: KONAGAI, Satoshi , TANAKA, Hiroaki , YAMAMOTO, Hiroko , SAKAGAMI, Hideki
- 申请人： Astellas Pharma Inc.
- 申请人地址： 5-1, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 JP
- 专利权人： Astellas Pharma Inc.
- 当前专利权人： Astellas Pharma Inc.
- 当前专利权人地址： 5-1, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 JP
- 代理机构： Bates, Philip Ian
- 优先权： JP2014109952 20140528
- 国际公布： WO2015182628 20151203
- 主分类号： A61K31/497
- IPC分类号： A61K31/497 ; A61P35/00 ; A61P35/02
摘要：
[Problem]
Provided is a pharmaceutical composition for treating cancer in which one or more kinases of BTK, JAK3, and ITK is involved.
[Means for Solution]
The present inventors studied compounds having a BTK inhibiting effect, a JAK3 inhibiting effect and an ITK inhibiting effect, and confirmed that a specific pyrazine carboxamide compound has the BTK inhibiting effect, the JAK3 inhibiting effect, and the ITK inhibiting effect, and that a pharmaceutical composition comprising the compound as an active ingredient has a therapeutic effect on cancer in which one or more kinases of BTK, JAK3 and ITK is involved, in another aspect, cancer in which BTK is overexpressed or activated, in another aspect, cancer in which a B cell receptor signal is activated, in still another aspect, cancer in which JAK3 is activation-mutated or activated, and in still another aspect, cancer in which ITK is activated, thereby completing the present invention.
Provided is a pharmaceutical composition for treating cancer in which one or more kinases of BTK, JAK3, and ITK is involved.
[Means for Solution]
The present inventors studied compounds having a BTK inhibiting effect, a JAK3 inhibiting effect and an ITK inhibiting effect, and confirmed that a specific pyrazine carboxamide compound has the BTK inhibiting effect, the JAK3 inhibiting effect, and the ITK inhibiting effect, and that a pharmaceutical composition comprising the compound as an active ingredient has a therapeutic effect on cancer in which one or more kinases of BTK, JAK3 and ITK is involved, in another aspect, cancer in which BTK is overexpressed or activated, in another aspect, cancer in which a B cell receptor signal is activated, in still another aspect, cancer in which JAK3 is activation-mutated or activated, and in still another aspect, cancer in which ITK is activated, thereby completing the present invention.
信息查询
IPC分类:
